Filing Details

Accession Number:
0001209191-14-042215
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-18 10:39:58
Reporting Period:
2014-06-16
Filing Date:
2014-06-18
Accepted Time:
2014-06-18 10:39:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1516479 Insys Therapeutics Inc. INSY Pharmaceutical Preparations (2834) 510327886
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1033150 N John Kapoor 444 South Ellis Street
Chandler AZ 85224
Yes No Yes No
1575551 1989 20 September Dated Trust Kapoor N John C/O Insys Therapeutics, Inc.
444 South Ellis Street
Chandler AZ 85224
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-06-16 3,000 $25.85 21,172,805 No 4 P Indirect By Trust
Common Stock Acquisiton 2014-06-16 2,000 $26.53 21,174,805 No 4 P Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Trust
No 4 P Indirect By Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 15,991 Direct
Common Stock 28,144 Indirect By Partnership
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.42994 to $26.3259, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  2. By The John N. Kapoor Trust dated September 20, 1989.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.50994 to $26.5599,inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  4. By EJ Financial/NEO Management, L.P. of which the reporting person is Managing General Partner.